Hemophilia A Clinical Trials

425 clinical trials for Hemophilia A across international registries, including 59 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B — RECRUITING · PHASE3
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A — RECRUITING · PHASE3
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A — RECRUITING · PHASE3
• A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A — RECRUITING · PHASE1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A — RECRUITING · PHASE1
• A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) — RECRUITING · PHASE1
• Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis — RECRUITING
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors — RECRUITING · PHASE3
• Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa — RECRUITING · PHASE4
• Lentiviral FVIII Gene Therapy — RECRUITING · PHASE1
• A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A — RECRUITING
• An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency — RECRUITING · PHASE1
• A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab — RECRUITING · PHASE4
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively — RECRUITING · PHASE3
• Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery — RECRUITING · PHASE4
• Synovial Proliferation on Routine Ultrasound: Active or Inactive? — RECRUITING
• SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis — RECRUITING · PHASE3
• Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders — RECRUITING
• ATHNdataset Registry — RECRUITING
• Joint Health, Balance and Quality of Life in Adults With Hemophilia A — RECRUITING
• A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A — RECRUITING · PHASE3
• Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs — RECRUITING · PHASE2
• Hemophilia A Research Program — RECRUITING
• National Longitudinal Cohort of Hematological Diseases — RECRUITING
• Multicenter observational study for patients with haemophilia A for treatment with efanesoctocog alfa (Altuvoct®) during surgical operations — RECRUITING
• A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) — RECRUITING
• Long-term Anticoagulation in a Patient With Severe Hemophilia A — RECRUITING
• To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A — RECRUITING · PHASE3
• A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan — RECRUITING
• Treatment of Hemophilia A Patients With FVIII Inhibitors — RECRUITING
• AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX — RECRUITING · PHASE3
• Gene Therapy for Chinese Hemophilia A — RECRUITING · NA
• Safety and Efficacy Study of NGGT003 in Hemophilia A Patients — RECRUITING · PHASE1
• A Study of FVIII Gene Therapy for Hemophilia A — RECRUITING · PHASE1
• Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis — RECRUITING · NA
• Manual Therapy in Hemophilic Arthropathy of the Ankle — RECRUITING · NA
• Measurement Properties in People with Hemophilia — RECRUITING · NA
• SYNOVIIIUS: PROSPECTIVE INTERVENTIONAL STUDY OF EFFECTIVENESS OF EFANESOCTOCOG ALFA PROPHYLAXIS ON SYNOVIAL HYPERTROPHY IN PATIENTS WITH HEMOPHILIA A — RECRUITING
• Longitudinal Cohort of Thrombosis and Hemostasis Diseases — RECRUITING
• OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF MIM8 IN PARTICIPANTS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS — RECRUITING
• Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A — RECRUITING
• World Bleeding Disorders Registry — RECRUITING
• A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF NXT007 IN PERSONS WITH SEVERE OR MODERATE HEMOPHILIA A — RECRUITING · PHASE1
• OPEN-LABEL SAFETY STUDY IN ADULTS AND ADOLESCENTS WITH HAEMOPHILIA A WITH AND WITHOUT FVIII INHIBITORS SWITCHING DIRECTLY FROM EMICIZUMAB PROPHYLAXIS TO NNC0365-3769 (MIM8) PROPHYLAXIS — RECRUITING
• German Pediatric Hemophilia Research Database — RECRUITING
• ASC618 Gene Therapy in Hemophilia A Patients — RECRUITING · PHASE1
• AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS — RECRUITING
• A PHASE 3, SINGLE-ARM, MULTICENTER, MULTINATIONAL, OPEN-LABEL, ONE-WAY CROSSOVER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED >/= 12 YEARS WITH SEVERE HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX — RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS — RECRUITING
• OPEN-LABEL STUDY INVESTIGATING EFFICACY, SAFETY AND PHARMACOKINETICS OF CONCIZUMAB PROPHYLAXIS IN CHILDREN BELOW 12 YEARS WITH HAEMOPHILIA A OR B WITH OR WITHOUT INHIBITORS — RECRUITING

Refine this search